Abstract
Cardiac complications are a major cause of perioperative morbidity and mortality in patients undergoing colorectal cancer surgery. A quick and reliable system for predicting postoperative cardiac morbidity is needed to predict cardiac events in order to improve outcome in surgery. The aim of this study was to investigate the role of the biochemical marker NT-proBNP in the prediction of postoperative all-cause mortality, cardiac-related mortality and cardiovascular events in patients undergoing colorectal cancer resections.
100 consecutive patients undergoing colorectal cancer surgery were prospectively recruited. Blood samples were taken preoperatively, 24h, 48h and 5-7 postoperative days to measure NT-proBNP levels. The predictive power of NT-proBNP levels was assessed using Receiver Operating Characteristics (ROC) curves.
Cardiac-related morbidity and mortality was 9%. Of eleven deaths, 5 were cardiac-related. Preoperative NT-proBNP was a good predictor of death with ROC area under curve (AUC) of 0.83 (95% C.I. 0.673, 0.993) a strong predictor of cardiac death with AUC of 0.914 (95% C.I. 0.823, 1.000) and a good predictor of cardiac complications with AUC of 0.875 (95% C.I. 0.757, 0.993). NT-proBNP levels 24 hours and 48 hours postoperatively were also strongly predictive of postoperative cardiac morbidity and mortality.
Pre- and postoperative NT-proBNP have a role in predicting postoperative death and cardiac complications. This may have significant implications in the planning of postoperative care for high-risk patients.
Author Contributions
Copyright© 2019
Youssef Haney, et al.
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Competing interests The authors have declared that no competing interests exist.
Funding Interests:
Citation:
Introduction
Cardiac complications are a major cause of perioperative morbidity and mortality in patients undergoing colorectal cancer surgery. One important aim of preoperative evaluation is to identify patients with significant coronary artery disease who may be at risk of cardiac complications following surgery. Many studies have looked into factors that might adversely affect these cardiac events and they include increasing age, New York Heart Association class, left ventricular ejection fractions, diabetes mellitus and lower blood pressure. Recent published literature has indicated that Brain Natriuretic Peptide (BNP) and its related compound, N-terminal fragment pro B-type Natriuretic Peptide (NT-proBNP), can be used to identify patients at high risk of developing major adverse cardiac events following non-cardiac surgery. The aim of this study was to investigate the role of the biochemical marker NT-proBNP in the prediction of postoperative all-cause mortality, cardiac-related mortality and cardiovascular events in patients undergoing colorectal cancer resections.
Results
Of the 100 patients recruited, 66 were male and 34 were female, with a median age of 72 years (range 39-90). Of the 100 patients, there were 11 postoperative deaths, of which 5 were due to cardiac causes. These included 4 myocardial infarctions and one patient with acute left ventricular failure and atrial fibrillation. There were 9 patients with cardiac complications including the 5 cardiac-related deaths. The causes of non-cardiac death (n=6) were pneumonia (n=2), MRSA sepsis from necrotic toe (n=1), Clostridium difficile sepsis (n=1), diarrhoea sepsis (n=1) and sepsis leading to MOF (n=1). Tn-T levels were elevated in 11 patients within 1 week postoperatively. Death from MI accounted for 4, there were 2 silent MI’s, 4 mild Tn elevations indicating minor myocardial injury (but not diagnostic of myocardial infarction) and 1 mild elevation from a patient who died from pneumonia leading to multiorgan failure. For all-cause mortality, the ROC curve AUC was 0.83 (95% c.i. 0.673, 0.993), making preoperative NT-proBNP a good predictor of postoperative death ( NT-proBNP values 24h post op were poorly predictive of death from all causes with AUC=0.754 (95% c.i. 0.575, 0.934), but were good predictors of cardiac death and cardiac complications, with AUC = 0.876 (95% c.i. 0.683, 1.000) and 0.840 (95% c.i. 0.659, 1.000) respectively. NT-proBNP values 48h post op, were not good predictors of death from all causes with AUC=0.748 (95% c.i. 0.560, 0.936). However for prediction of cardiac mortality AUC was 0.907 (95% c.i. 0.807, 1.000) making it a strong predictor. For cardiac complications 48h NT-proBNP levels were very strongly predictive (Figure 9) with, AUC=0.939 (95% c.i. 0.878, 0.999). Numbers in parentheses are 95% confidence intervals
Characteristic
Number of Patients
Operation
Right sided resection
42
Anterior resection
36
APR
5
Left sided other
15
Other
2
Postoperative histology
A
13
B
51
C1
23
C2
10
Other
3
RCRI Class
Number of Patients
Cardiac complications-survivors
Cardiac deaths
Other deaths
I
0
0
0
0
II
76
4
2
3
III
15
0
1
2
IV
9
0
2
1
Time point of
Predicted Variable
Area under the curve (AUC)
Using NT-proBNP cut-off > 40pmol/l
Using NT-proBNP cut-off > 90pmol/l
NT-proBNP measureent
sens
spec
ppv
npv
sens
spec
ppv
npv
Preoperative
Death
0.83
73%
80%
31%
96%
55%
92%
46%
94%
(0.673-0.993)
(46-99)
(71-88)
(13-49)
(91-100)
(25-84)
(87-98)
(19-73)
(89-99)
Cardiac death
0.914
80%
77%
15%
99%
80%
91%
31%
99%
(0.823-1.000)
(45-100)
(68-85)
(2-29)
(96-100)
(45-100)
(85-96)
(6-56)
(97-100)
Cardiac Complications
0.875
75%
78%
23%
97%
75%
92%
46%
98%
(0.757-0.993)
(45-100)
(70-87)
(7-39)
(94-100)
(45-100)
(87-98)
(19-73)
(95-100)
24h postoperative
Death
0.754
91%
38%
15%
97%
64%
72%
22%
94%
(0.575-0.934)
(74-100)
(28-48)
(7-24)
(92-100)
(35-92)
(63-81)
(8-36)
(89-100)
Cardiac death
0.876
100%
37%
8%
100%
80%
71%
13%
99%
(0.683-1.000)
(100-00)
(27-47)
(1-14)
(100-00)
(45-100)
(61-80)
(1-24)
(96-100)
Cardiac Complications
0.84
88%
37%
11%
97%
75%
72%
19%
97%
(0.659-1.000)
(65-100)
(27-47)
(3-18)
(92-100)
(45-100)
(63-81)
(5-32)
(93-100)
48h postoperative
Death
0.748
90%
25%
12%
96%
70%
58%
16%
94%
(0.560-0.936)
(71-100)
(16-34)
(5-19)
(87-100)
(42-98)
(48-68)
(5-27)
(88-100)
Cardiac death
0.907
100%
24%
5%
100%
100%
57%
9%
100%
(0.807-1.000)
(100-00)
(16-33)
(0.2-10)
(100-00)
(100-00)
(47-67)
(0.6-18)
(100-00)
Cardiac Complications
0.939
100%
25%
9%
100%
100%
59%
16%
100%
(0.876-0.999)
(100-00)
(16-34)
(3-16)
(100-00)
(100-00)
(49-69)
(5-27)
(100-00)
Discussion
Emerging data from published literature indicates that preoperative measurement of BNP and NT-proBNP is a good predictor for complications after cardiac surgery This study has demonstrated that both pre-operative and postoperative measurement of NT-proBNP can help in identifying patients at high risk of major adverse events following colorectal cancer surgery. Pre-operative NT-proBNP levels may be able to predict the pre-operative cardiac status of patients but do not necessary reflect the variable dynamic sequences of postoperative stress responses which may result in adverse cardiac events. On the other hand, the postoperative measurement of NT-proBNP takes these factors into consideration, particularly with respect to the risk of cardiac death or cardiac complications. The use of NT-proBNP as a predictive preoperative biochemical marker has significant potential clinical applications. It is envisaged that patients with high preoperative NT-proBNP levels, indicating a high risk of postoperative cardiovascular events, could be referred for cardiac optimisation. Valuable hospital resources, such as the use of intensive care monitoring, can also be targeted for patients who fall in this group. It remains to be seen whether such interventions would have any effect on patient morbidity or mortality. In our study, the greatest power of the preoperative NT-proBNP value was as a negative predictor. This means that normal NT-proBNP values were associated with low risks of cardiac events. This seems to correlate with the results found in heart failure where the European Society of Cardiology Task force guidelines for the treatment of chronic heart failure state that natriuretic peptides may be most useful clinically as a rule out test due to consistent and very high negative predictive values. In our study, 11 patients (11%) had a rise in Tn-T post-operatively, 6 of which were not apparent clinically and 2 of which were diagnosed as silent myocardial infarctions. These 2 patients were referred to cardiologists and treated for myocardial infarction, with appropriate cardiology follow-up. The routine measurement of post operative Tn-T, although useful for these 2 patients, may not be justified in the routine care of these patients when the cost of the test is considered. However, this has not been formally assessed in a cost-benefit analysis. Previous work on higher risk patients, undergoing elective and emergency aortic aneurysm repair, has yielded much higher proportions of patients having Tn-T rises postoperatively. The study has several limitations. Firstly, it was carried out in one centre, so it may not be possible to apply the results of this study to another population because of different prevalence of cardiac disease. Secondly data on confounding factors such as intraoperative blood loss and surgical contamination was not collected in this study. These could potentially heavily influence the outcome after surgery. Remarkably, there were no anastomotic leaks diagnosed in this series of patients. It is possible that some of these cardiac complications could be attributed to undiagnosed leaks, as one previous study demonstrated that approximately 40% of patients having cardiac symptoms following a restorative colorectal resection, in fact had suffered an anastomotic leak. The NT-proBNP test is safe and convenient, requiring only a routine venepuncture. Currently a routine NT-proBNP test will cost the NHS £25.00 per patient and this is relatively cheap to screen some of the high-risk patients. However, there are no data to support the use of NT-proBNP in the general screening of asymptomatic populations for heart failure prior to surgery. What is clear from our study is that NT-proBNP measurements are useful as an adjunct to other clinical tools to determine the risks of patients undergoing non-cardiac surgery. With the current emerging evidence, NT-proBNP has the potential to be used in clinical practice. Patients with high risks of cardiovascular disease should have a screening NT-proBNP blood test. Patients with elevated NT-proBNP should be referred to a cardiologist for consideration of additional stress testing or echocardiogram, to assess the presence and extent of coronary artery disease. Conversely patients with normal NT-proBNP tests have the potential to avoid unnecessary patient referral for echocardiography or stress testing.